University of the Ryukyus · Faculty of Medicine · 講師

Research keywordspulmonary tuberculosis biomarkers・COVID-19 clinical outcomes・community-acquired pneumonia・Cryptococcus neoformans immunity・Streptococcus pneumoniae host defense・Legionella pneumonia・Mycobacterium tuberculosis immunity・strongyloidiasis in Okinawa・respiratory pathogen PCR・imported malaria

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• Hemobilia and cholangitis in hereditary hemorrhagic telangiectasia.2020 · Hashioka H, Kami W, Miyazato K, Miyagi K, Hokama A, Fujita J
• Serum levels of receptor-interacting protein kinase-3 in patients with COVID-19.2020 · Nakamura H, Kinjo T, Arakaki W, Miyagi K, Tateyama M, Fujita J
• Diagnostic performance of serum interferon gamma, matrix metalloproteinases, and periostin measurements for pulmonary tuberculosis in Japanese patients with pneumonia.2020 · Yamauchi M, Kinjo T, Parrott G, Miyagi K, Haranaga S, Nakayama Y, Chibana K, Fujita K, Nakamoto A, Higa F, Owan I, Yonemoto K, Fujita J
• Acute Hypertriglyceridaemia Caused by Tocilizumab in a Patient with Severe COVID-19.2019 · <p>Treatment with tocilizumab (TCZ) to block interleukin-6 (IL-6) signalling is predicted to mitigate cytokine release syndrome (CRS) caused by coronavirus disease 2019 (COVID-19). However, the adverse effects of TCZ on patients with COVID-19 remain unclear. We herein report a patient with COVID-19 treated with TCZ who developed acute hypertriglyceridaemia. Despite favipiravir treatment, acute respiratory distress syndrome developed in a 45-year-old patient with COVID-19; thus, TCZ was initiated. The triglyceride levels greatly increased after TCZ administration. Physicians should consider the negative impact of TCZ on the lipid profile in patients with COVID-19, although COVID-19-induced CRS itself may be an aggravating factor. </p>

• 沖縄県における夏のインフルエンザ流行パターンとウイルスのゲノム解析
• 沖縄県特有の土壌分布は特発性間質性肺炎の経過に影響をおよぼすのか？

• Official profile